A number of research firms have changed their ratings and price targets for AxoGen (NASDAQ: AXGN):
- 11/16/2026 – AxoGen was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 11/8/2026 – AxoGen was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 10/31/2026 – AxoGen was upgraded by Wall Street Zen from “hold” to “strong-buy”.
- 10/29/2026 – AxoGen had its price target raised by Leerink Partners from $52.00 to $56.00. They now have an “outperform” rating on the stock.
- 10/29/2026 – AxoGen had its “buy” rating reaffirmed by Lake Street Capital. They now have a $58.00 price target on the stock.
- 10/29/2026 – AxoGen had its price target raised by Barclays from $50.00 to $60.00. They now have an “overweight” rating on the stock.
- 10/29/2026 – AxoGen had its “outperform” rating reaffirmed by Raymond James Financial. They now have a $57.00 price target on the stock.
- 10/29/2026 – AxoGen had its price target raised by Canaccord Genuity Group from $55.00 to $60.00. They now have a “buy” rating on the stock.
- 10/29/2026 – AxoGen had its price target raised by Truist Financial from $53.00 to $60.00. They now have a “buy” rating on the stock.
- 10/29/2026 – AxoGen had its price target raised by Wells Fargo & Company from $48.00 to $56.00. They now have an “overweight” rating on the stock.
- 10/29/2026 – AxoGen had its price target raised by HC Wainwright from $53.00 to $56.00. They now have a “buy” rating on the stock.
- 10/28/2026 – AxoGen had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $60.00 price target on the stock.
- 10/28/2026 – AxoGen was given a new $65.00 price target by Mizuho.
- 10/23/2026 – AxoGen had its price target lowered by Barclays from $55.00 to $50.00. They now have an “overweight” rating on the stock.
- 10/12/2026 – AxoGen is now covered by Bank of America. They set a “buy” rating and a $52.00 price target on the stock.
- 10/6/2026 – AxoGen is now covered by Barclays. They set an “overweight” rating and a $55.00 price target on the stock.
- 10/6/2026 – AxoGen was upgraded by Barclays to “strong-buy”.
- 10/5/2026 – AxoGen had its “buy” rating reaffirmed by Lake Street Capital.
- 10/1/2026 – AxoGen had its price target lowered by Truist Financial from $60.00 to $53.00. They now have a “buy” rating on the stock.
- 10/1/2026 – AxoGen had its price target lowered by Truist Financial from $60.00 to $53.00. They now have a “buy” rating on the stock.
- 9/29/2026 – AxoGen was downgraded by Morgan Stanley to “hold”.
- 9/26/2026 – AxoGen was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/25/2026 – AxoGen had its price target raised by Raymond James Financial from $48.00 to $53.00. They now have an “outperform” rating on the stock.
AxoGen Stock Up 2.9%
NASDAQ AXGN traded up $1.58 during trading hours on Wednesday, reaching $56.95. 2,113,784 shares of the company’s stock were exchanged, compared to its average volume of 1,241,647. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.67 and a current ratio of 12.02. The company has a market capitalization of $3.40 billion, a price-to-earnings ratio of -87.62 and a beta of 1.21. The company’s 50-day moving average is $43.58 and its two-hundred day moving average is $40.65. AxoGen, Inc. has a one year low of $23.61 and a one year high of $59.72.
AxoGen (NASDAQ:AXGN – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.08. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. The company had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $73.45 million. On average, analysts forecast that AxoGen, Inc. will post -0.36 EPS for the current fiscal year.
Insider Buying and Selling
In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the completion of the transaction, the director owned 10,650 shares of the company’s stock, valued at $529,305. This represents a 24.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.44% of the company’s stock.
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
Featured Stories
- Five stocks we like better than AxoGen
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AxoGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
